Inventor · disambiguated record
Hilde Adi Pierrette Revets
Also filed as: REVETS HILDE · REVETS HILDE ADI PIERRETTE
11 granted patents·13 pending applications·152 citations·filing 2002–2023
90Inventor score
Files withABLYNX NV8REVETS HILDE ADI PIERRETTE4Biotalys NV2UNIV BRUXELLES2VLAAMS INTERUNIV INST BIOTECH2
Top patents by PatentIndex Score
24 records- 0195US8975382B2Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumorsREVETS HILDE ADI PIERRETTE·Filed 2008·Granted Mar 10, 2015·42 cites·16 claims
- 0295US8188223B2Serum albumin binding proteinsBEIRNAERT ELS·Filed 2006·Granted May 29, 2012·60 cites·18 claims
- 0391US9969805B2Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumorsABLYNX NV·Filed 2015·Granted May 15, 2018·10 cites·20 claims
- 0488US8217140B2Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the sameREVETS HILDE ADI PIERRETTE·Filed 2009·Granted Jul 10, 2012·11 cites·18 claims
- 0586US12098378B2Anti-fungal polypeptidesBiotalys NV·Filed 2023·Granted Sep 24, 2024·1 cites·4 claims
- 0682US6936263B2Th1 inducing natural adjuvant for heterologous antigensVLAAMS INTERUNIV INST BIOTECH·Filed 2002·Granted Aug 30, 2005·21 cites·10 claims
- 0781US9670275B2Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumorsABLYNX NV·Filed 2013·Granted Jun 6, 2017·3 cites·8 claims
- 0877US10808032B2Biological materials related to HER3ABLYNX NV·Filed 2018·Granted Oct 20, 2020·1 cites·20 claims
- 0975US9932403B2Biological materials related to HER3KNUEHL CHRISTINE·Filed 2011·Granted Apr 3, 2018·3 cites·8 claims
- 1061US2011028695A1Method for obtaining polypeptide constructs comprising two or more single domain antibodiesREVETS HILDE ADI PIERRETTE·Filed 2008·Application pending·0 cites
- 1157US10100110B2Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumorsABLYNX NV·Filed 2017·Granted Oct 16, 2018·0 cites·8 claims
- 1255US2023110053A1Anti-fungal polypeptidesBiotalys NV·Filed 2021·Application pending·0 cites
- 1350US2008199472A1Use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cellsVLAAMS INTERUNIV INST BIOTECH·Filed 2008·Application pending·0 cites
- 1450US2012253008A1Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the sameREVETS HILDE ADI PIERRETTE·Filed 2012·Application pending·0 cites
- 1549US2007031430A1ImmunoconjugatesUNIV BRUXELLES·Filed 2006·Application pending·0 cites
- 1649US2005048060A1ImmunoconjugatesFiled 2004·Application pending·0 cites
- 1748US2008267949A1Peptides capable of binding to serum proteinsABLYNX NV·Filed 2007·Application pending·0 cites
- 1847US2010129354A1Intranasal delivery of polypeptides and proteinsABLYNX NV·Filed 2007·Application pending·0 cites
- 1946US2007269422A1Serum albumin binding proteins with long half-livesABLYNX NV·Filed 2006·Application pending·0 cites
- 2045US7893026B2Treatment of EGFR-dependent tumors by ABIN (a20 -binding inhibitor of NF kappab)VIB VZW·Filed 2006·Granted Feb 22, 2011·0 cites·3 claims
- 2145US2006111294A1Use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cellsUNIV BRUXELLES·Filed 2005·Application pending·0 cites
- 2240US2011243954A1Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the sameABLYNX NV·Filed 2011·Application pending·0 cites
- 2339US2013012916A1Delivery of immunoglobulin variable domains and constructs thereofGLIDE PHARMACEUTICAL TECHNOLOGIES LTD·Filed 2011·Application pending·0 cites
- 2430US2011117113A1Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate themBESTE GERALD·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →